No abstract available.
Lymphoma, T-Cell* ; T-Lymphocytes*

No abstract available.
Lymphoma, T-Cell* ; T-Lymphocytes*

No abstract available.
Lymphoma, T-Cell ; T-Lymphocytes

No abstract available.
Lymphoma, T-Cell* ; T-Lymphocytes*

NK/T-cell lymphomas which are characterized by the biphenotype of the NK-cell and the T-cell are divided into nasal and non-nasal NK/T-cell lymphoma, non-nasal NK/T-cell lymphoma is then further subdivided into primary cutaneous and 4 subtypes of secondary cutaneous lymphoma such as nasal type, aggressive, blastic(blastoid), and other specific NK-like T-cell lymphoma. Primary cutaneous NK/T-cell lymphoma is a very rare condition and defined as a lack of extracutaneous disease for at least 6 months from the time of diagnosis. We herein report a case of non-nasal NK/T-cell lymphoma, which is consistent with primary cutaneous type.
Diagnosis ; Lymphoma* ; Lymphoma, T-Cell ; T-Lymphocytes

No abstract available.
Lymphoma ; Lymphoma, T-Cell ; T-Lymphocytes

No abstract available.
Lymphoma, T-Cell ; Panniculitis

No abstract available.
Lymphoma, T-Cell, Peripheral*

INTRODUCTION: Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma (PCAECTCL) is a rare subtype of cutaneous T-cell lymphoma characterized by widely distributed ulcerated lesions, epidermotropic infiltrates of CD8+ cytotoxic T cells, aggressive course, high tendency to spread to extranodal sites, poor response to conventional therapies and unfavorable prognosis.

CASE REPORT: We report a 76-year-old Filipino male presenting with eight-month history of erythematous scaly patches evolving into widespread ulcerated nodules, unresponsive to topical and systemic steroids. Histopathology revealed prominent epidermotropism and lichenoid infiltrate of atypical lymphocytes. Immunohistochemistry showed positivity for CD3, CD8, Ki67 (5-15%), CD7, CD2; indeterminate for TIA-1, with high background staining; and was negative for CD20, CD30, CD4, CD5, CD56, granzyme-B, TdT, Epstein-Barr encoding region in situ hybridization (EBER-ISH), consistent with PCAECTCL. No overt metastasis was detected. The patient underwent interferon alfa 2B therapy followed by three full cycles of CHOP chemotherapy. Improvement was seen as thinning of plaques and nodules and re-epithelialization of ulcers however, severe anemia and leukopenia ensued with therapy. He then succumbed to septic shock secondary to pneumonia during the height of the COVID-19 pandemic.

CONCLUSION: This case emphasizes that despite accurate diagnosis, polychemotherapy, and favorable response to therapy, complications may still arise contributing to the poor prognosis and low fi ve-year survival rate of this condition.

KEYWORDS: T-cell lymphoma, CD8 positive, neoplasms

Introduction: Primary Cutaneous Anaplastic Large Cell Lymphoma (PC-ALCL) is a rare Non-Hodgkin lymphoma (NHL) representing approximately 9% of all cutaneous lymphomas.3 It usually manifests as a slow-growing, solitary tumor which has a tendency to regress spontaneously. However, metastasis is reported in 5-10% of cases.2 Case Summary: Our case is an 81-year-old female with a four-month history of an enlarging nodule on the left upper back. The initial impression was a malignant cutaneous tumor. Histopathology revealed epidermotropic large atypical lymphocytes and diffuse infiltrates of hyperchromatic, pleomorphic mononuclear cells and lymphocytes. Immunohistochemistry showed CD3+, CD20-, CD30+, epithelial membrane antigen (EMA)- and anaplastic lymphoma kinase (ALK)- consistent with PC-ALCL. Metastatic work-up revealed pulmonary involvement. The patient underwent two cycles of multi-agent chemotherapy with marked improvement. However, patient declined further treatment and expired five months after the diagnosis. Conclusion This case emphasizes that although PC-ALCL commonly presents with an indolent course, extracutaneous spread can occur. Prompt treatment with chemotherapy increases survival significantly with a cure rate of 92%.2
Lymphoma, T-Cell ; Neoplasms